Clinical Trials Logo

Partial-thickness Burn clinical trials

View clinical trials related to Partial-thickness Burn.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT04839523 Recruiting - Clinical trials for Partial-thickness Burn

Performance and Safety of Exufiber Ag+ and Exufiber on Partial Thickness Burns

Start date: March 10, 2021
Phase: N/A
Study type: Interventional

This a multi-center, open label, non-comparative, study that will evaluate the clinical safety and performance of Exufiber Ag+ and Exufiber dressings, separately, when used as intended in moderate to high exuding partial thickness burns (PTBs) through assessment of wound progression from baseline to the Subject's last clinical follow-up visit. Sixty-eight (68) eligible subjects, with moderate to high exuding partial-thickness burns, will be selected for treatment with either Exufiber Ag+ silver-coated gelling dressing, or Exufiber gelling dressing. The study will last 5 weeks, with a requirement of 5 study visits in total, including dressing changes at each study visit.

NCT ID: NCT03709069 Recruiting - Clinical trials for Partial-thickness Burn

Effect of Enteral Albumin on Healing of Superficial Partial Thickness Fresh Flame Burns of Adults

Start date: November 10, 2018
Phase: N/A
Study type: Interventional

Patients with 10 to 20% Superficial partial thickness fresh flame burn will be recruited. Burn thickness will be confirmed by using Laser Doppler. After randomly allocating into two groups, one group will receive enteral supplemental albumin in the form of boiled egg along with routine diet while other group will receive only routine diet. Effect of burn healing will be noted in terms of epithelization, oedema, pain and redness and days of hospital stay

NCT ID: NCT03564795 Recruiting - Clinical trials for Partial-thickness Burn

Effectiveness of KeraStat Gel for Improved Cosmesis of Partial Thickness Burns

Start date: August 31, 2018
Phase: N/A
Study type: Interventional

A randomized, controlled, 30-subject, within-subject trial for examining the effectiveness of KeraStat Gel, as opposed to the institutional standard of care, silver sulfadiazine, in improving cosmesis of the healed wound.